Pharm2Farm reported on Thursday the availability of the Pro-Larva mask that integrates the unique British technology based on copper nanoparticles to create an effective virucidal barrier against Covid-19 and other types of viruses, including the flu virus.
The company added that the Pro-Larva mask is the new antiviral mask that kills 99.9% of Covid-19 in the first five minutes of contact. The new revolutionary device, unlike the traditional masks, offers an unsurpassed level of protection against viruses, not only for those around the wearer but also for the wearer.
According to the company, the Pro-Larva mask is designed for hospitals, retirement homes, schools, retail and leisure sectors.
A spin out from Nottingham Trent University, Pharm2Farm Ltd produces and sells these masks through an exclusive license from NTU.
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Tissue Regenix secures CE and UKCA certifications for OrthoPure XT
Terumo Corporation expands stroke portfolio in EMEA with SOFIA Flow 88 catheter launch
Crossject advances ZENEO manufacturing with scalable aseptic filling module ahead of product rollout
Mindray unveils BeneVision V Series at Euroanaesthesia 2025, advancing precision monitoring
Unicon Pharma and VRR Life Sciences partner support digital transformation in life sciences
Median Technologies submits 510(k) application for eyonis LCS lung cancer screening software
Tristel secures FDA clearance for Ophthalmic Disinfectant Tristel OPH